Dr. Bryan P. Schneider earned his B.S. from the University of Evansville in 1995. Upon completion, he continued his education at Indiana University (IU) where he earned his M.D. in 1999. He completed an internal medicine residency at the IU School of Medicine (IUSM) in 2001 and later completed a hematology/oncology fellowship at IUSM in 2005. Since joining the IUSM faculty as an assistant professor in 2005, Schneider has held numerous appointments and titles at the university. In 2019, he was awarded the additional honorary title Vera Bradley Professor of Oncology.
Schneider devotes his clinical time to caring for breast cancer patients as a medical oncologist and has a special interest in novel therapeutic agents. He is the model example of a translational scientist as his lab work is both an extension of and complementary to his clinical interest. His laboratory focus is on the pharmacogenetics of breast cancer therapeutics. His biomarker work to date has opened the door for the potential enrichment of patient selection for bevacizumab. Based on his early work, he has designed correlative trials in collaboration with multiple groups to better guide proper patient selection for these agents. He is extensively published in the area of therapeutic individualization (i.e., finding the right drug for each patient).
He is a recipient of the prestigious Komen Promise Award and a member of the Komen Scientific Advisory Council. Dr. Schneider is the chair of the Educational Symposium for the Developmental Therapeutics Committee, the vice-chair of the Pharmacogenetics Committee, and a member of the Breast Cancer Committee for the Eastern Cooperative Oncology Group (ECOG). He is also a member of the Consortium on Breast Cancer Pharmacogenetics (CoBRA) and the Pharmacogenetics Research Network (PGRN).